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RESEARCH ARTICLE SUBJECT COLLECTION: MODEL SYSTEMS IN DRUG DISCOVERY
A rapid in vivo screen for pancreatic ductal adenocarcinoma
therapeutics
Ozhan Ocal1, Victor Pashkov1, Rahul K. Kollipara2, Yalda Zolghadri1,3, Victoria H. Cruz4, Michael A. Hale5,
Blake R. Heath1, Alex B. Artyukhin6, Alana L. Christie7, Pantelis Tsoulfas8, James B. Lorens9, Galvin H. Swift5,
Rolf A. Brekken1,4 and Thomas M. Wilkie1,*
ABSTRACT
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause
of cancer-related deaths in the United States, and is projected to be
second by 2025. It has the worst survival rate among all major
cancers. Two pressing needs for extending life expectancy of affected
individuals are the development of new approaches to identify
improved therapeutics, addressed herein, and the identification of
early markers. PDA advances through a complex series of
intercellular and physiological interactions that drive cancer
progression in response to organ stress, organ failure, malnutrition,
and infiltrating immune and stromal cells. Candidate drugs identified
in organ culture or cell-based screens must be validated in preclinical
models such as KIC (p48Cre;LSL-KrasG12D;Cdkn2af/f ) mice, a
genetically engineered model of PDA in which large aggressive
tumors develop by 4 weeks of age. We report a rapid, systematic and
robust in vivo screen for effective drug combinations to treat Kras-
dependent PDA. Kras mutations occur early in tumor progression in
over 90% of human PDA cases. Protein kinase and G-protein
coupled receptor (GPCR) signaling activates Kras. Regulators of G-
protein signaling (RGS) proteins are coincidence detectors that can
be induced by multiple inputs to feedback-regulate GPCR signaling.
We crossed Rgs16::GFP bacterial artificial chromosome (BAC)
transgenic mice with KIC mice and show that the Rgs16::GFP
transgene is a KrasG12D-dependent marker of all stages of PDA,
and increases proportionally to tumor burden in KIC mice. RNA
sequencing (RNA-Seq) analysis of cultured primary PDA cells
reveals characteristics of embryonic progenitors of pancreatic ducts
and endocrine cells, and extraordinarily high expression of the receptor
tyrosine kinase Axl, an emerging cancer drug target. In proof-of-
principle drugscreens,we find thatweanlingKICmicewithPDA treated
for 2 weeks with gemcitabine (with or without Abraxane) plus inhibitors
of Axl signaling (warfarin andBGB324) have fewer tumor initiation sites
and reduced tumor size comparedwith the standard-of-care treatment.
Rgs16::GFP is therefore an in vivo reporter of PDA progression and
sensitivity to new chemotherapeutic drug regimens such as Axl-
targeted agents. This screening strategy can potentially be applied to
identify improved therapeutics for other cancers.
KEY WORDS: Rgs16::GFP reporter, Kras, Rapid in vivo screen,
Pancreatic cancer combination therapy, Gas6, Axl, Warfarin,
Gemcitabine, Abraxane
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause
of cancer-related deaths but is predicted to become more common
owing to its association with smoking, diet, obesity and type 2
diabetes (Pannala et al., 2008; Rahib et al., 2014; Siegel et al., 2015).
Three major classifications of pancreatic precancerous lesions are
associatedwith progression to PDA: PanIN (pancreatic intraepithelial
neoplasia), IPMN (intraductal papillary mucinous neoplasm) and
MCN (mucinous cystic neoplasm) (Distler et al., 2014). Precancerous
lesions can be common in the elderly or obese. For example, early
PanINs were found in 65% of obese patients, and their presence was
associated with intravisceral fat, and pancreatic intralobular fibrosis
and fat (Rebours et al., 2015). IPMNs are the next most common
pancreatic precancerous lesion associated with PDA (Maitra et al.,
2005). They are found in the pancreatic main and branching ducts.
MCNs occur predominantly in females, predominantly in the
peripheral pancreas (Thompson et al., 1999).
Recent mathematical predictions attribute spontaneous mutations
during cell division as initiators of PDA, making early detection and
effective therapy the only two elements determining survival
(Tomasetti and Vogelstein, 2015). Unfortunately, PDA symptoms
present late in disease progression and, other than surgical resection,
limited progress has been made in developing effective treatments
after gemcitabine was introduced as a first-line therapy for advanced
PDA (Burris et al., 1997). Gemcitabine treatment alone or after
resection is marginally effective in prolonging survival. One of the
two predominant therapeutic regimens is gemcitabine combined
with nab-paclitaxel (Abraxane), which was shown to increase
survival to 8.5 months, compared with 6.7 months for patients who
received gemcitabine alone (Von Hoff et al., 2013). In a follow-up
study, 3% of patients in the gemcitabine plus nab-paclitaxel group
were still alive after 42 months of treatment compared with none in
the gemcitabine only group (Goldstein et al., 2015). The primary
mechanism of function of paclitaxel is interference with
microtubule depolymerization leading to mitotic failure (Schiff et
al., 1979, 1980). Nab-paclitaxel has been shown to provide better
tolerance and absorption than paclitaxel. In addition, nab-paclitaxel
augments gemcitabine efficacy by reducing the level of its
metabolizing enzyme, cytidine deaminase (Ibrahim et al., 2002;
Frese et al., 2012). However, tumors are often resistant to thisReceived 1 April 2015; Accepted 13 August 2015
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combination (Neesse et al., 2014). The other common drug treatment,
FOLFIRINOX, consisting of four different chemotherapy agents, is
more effective but less well-tolerated (Becker et al., 2014; Moorcraft
et al., 2014; Haeno et al. 2012). Therefore, there is a need for a
systematic and robust in vivo screen that can accelerate the pace of
discovery of improved PDA therapeutics.
PDA initiates as ductal neoplasia, derived from any of three
pancreatic adult cell types – ductal progenitor cells, centroacinar
cells, or acinar cells that have undergone acinar-to-ductal metaplasia
(ADM) (Bonner-Weir et al., 2004; Rovira et al., 2010; von Figura
et al., 2014). In humans, activated Kras and inactivated Cdkn2a
are the earliest and most common genetic mutations identified in
disease progression (Hezel et al., 2006; Iacobuzio-Donahue et al.,
2012). Genetically engineered mouse models (GEMMs) based on
these mutations have been developed to investigate PDA initiation
and propagation. In the present study, we use KC (p48Cre;LSL-
KrasG12D) and KIC (p48Cre;LSL-KrasG12D;Cdkn2af/f ) mice. Both
lines form tumors because they express activated KrasG12D (KIC
also has inactivation of the tumor suppressor Cdkn2a) in all three
pancreatic lineages – ducts, acinar and endocrine cells – under
control of the p48 (Ptf1a) promoter. By contrast, IC mice (p48Cre;
Cdkn2af/f ) never form tumors (Aguirre et al., 2003). KIC mice are
an excellent GEMM for PDA therapeutic screens because neoplasia
develops early, between 2 to 3 weeks of age, and large aggressive
tumors develop in all mice by 4 weeks of age (Aguirre et al., 2003).
PDA is themost frequent major cancer harboring Rasmutations (e.
g. KrasG12D) (Pylayeva-Gupta et al., 2011). Kras mutations are found
in over 90% of human PDA cases (Iacobuzio-Donahue et al., 2012).
KrasG12D expression is necessary but not sufficient to initiate
neoplasia; GTP binding is required to activate KrasG12D (Huang
et al., 2014). Ras guanine nucleotide exchange factors (Ras-GEFs)
catalyzeGDP dissociation, and subsequent GTP binding to Ras (Jeng
et al., 2012). Protein kinase and G-protein coupled receptor (GPCR)
signaling can stimulate Ras-GEFs to promote KrasG12D-dependent
neoplasia (van Blesen et al., 1995; Kahn, 2014). Regulators of G-
protein signaling (RGS) proteins are GTPase activating proteins
(GAPs) for the Gi- and Gq-alpha subunits of heterotrimeric G
proteins (Berman et al., 1996). Interestingly, RGS-resistant mutations
in Gαq (and Gαs) were found in cells isolated from pancreatic cysts
(Wu et al., 2011). RGS proteins are coincidence detectors that can be
induced by and integrate multiple inputs to feedback-regulate the
GPCR arm of the pathway, by virtue of their Gα-GAP activity (Ross
andWilkie, 2000;Huang et al., 2006;Villasenor et al., 2010; Pashkov
et al., 2011). The induction of RGS proteins can therefore be
monitored to report hyperactivated Ras signaling (Dohlman et al.,
1996; Dignard et al., 2008). Because Ras remains an elusive drug
target (Stephen et al., 2014), we developed an in vivo screen for PDA
therapeutics that is responsive to Kras signaling.
We previously described expression of an Rgs16::GFP bacterial
artificial chromosome (BAC) transgene during embryonic and
postnatal pancreas development in pancreatic progenitors, endocrine
cells and duct cells (Villasenor et al., 2010). GFP was expressed in
ducts and islet β-cells during neonatal pancreas development butwas
not detected in euglycemic adult mice. Rgs16::GFP was reactivated,
first in ducts, then islet β-cells, under conditions of chronic insulin
demand or hyperglycemia in mouse models of type 1 and type 2
diabetes, and during gestation. In humans, Rgs16 expression was
observed in ducts of pancreatic cancer patients prior to detectable
metastasis (Kim et al., 2010). Chronic stress might induce Rgs16 in
progenitor cells within the pancreatic ductal epithelium (Bonner-
Weir et al., 2004; Villasenor et al., 2010). To test whether Rgs16 is
an early marker of PDA, we crossed the Rgs16::GFP transgene into
KIC mice. Here, we show that the Rgs16::GFP transgene is a
KrasG12D-dependent marker of all stages of neoplasia in KICmice –
IPMN, PanIN and PDA (Hruban et al., 2000; Maitra et al., 2005).
The distribution and intensity of Rgs16::GFP expression is
proportional to and coincident with tumor burden.
In a proof-of-principle for drug screens, we find that weanling
KIC mice with PDA treated with the standard-of-care combination
of gemcitabine and nab-paclitaxel (Abraxane) (Masellis et al., 2009;
Frese et al., 2012; Von Hoff et al., 2013; Neesse et al., 2014) for 2
weeks have significantly lower Rgs16::GFP expression, and
reduced tumor size and occurrence. The Axl tyrosine kinase
receptor is associated with aggressive cancer and poor patient
outcome in breast, liver and pancreatic cancer (Gjerdrum et al.,
2010; Song et al., 2011; Reichl et al., 2015). Axl, and its γ-
carboxylated ligand, Gas6, are associated with drug-resistant tumor
relapse (Linger et al., 2008; Song et al., 2011; Schmidt et al., 2012;
Kirane et al., 2015). We therefore evaluated novel combinations of
standard-of-care PDA chemotherapeutics with Gas6/Axl signaling
inhibitors in our rapid in vivo PDA therapeutic assay. We show that
warfarin or an Axl kinase inhibitor (BGB324), in combination with
gemcitabine and nab-paclitaxel, significantly reduce tumor
TRANSLATIONAL IMPACT
Clinical issue
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of
cancer-related US deaths, and is projected to be the second leading
cause by 2025 because of its association with smoking, obesity and type
2 diabetes. PDA has the worst survival rate of any major cancer so
far. The current standard-of-care provides only modest therapeutic
gains. The two most desperately needed advances for extending life
expectancy of individuals with PDA are improved therapeutics and the
identification of early markers. PDA advances through a complex
series of intercellular and physiological interactions that drive cancer
proliferation in response to organ stress, and infiltrating immune and
stromal cells, causing organ failure and subsequent malnutrition. Kras
mutations occur early in tumor progression in over 90% of human PDA.
However, Kras is refractory to direct inhibitors.
Results
In this study, the authors report a rapid, systematic and robust in vivo
screen for effective drug combinations to treat Kras-dependent PDA.
Protein kinase andG-protein coupled receptor (GPCR) signaling activates
Kras. Regulators of G-protein signaling (RGS) proteins are coincidence
detectors that can be induced by multiple inputs to feedback-regulate
GPCR signaling. The Rgs16::GFP transgene is a KrasG12D-dependent
marker of all stages of PDA neoplasia and its expression increases
proportionally to tumor burden in KIC mice – a genetically engineered
mouse model of PDA. RNA sequencing analysis of cultured primary PDA
cells shows characteristics of embryonic progenitors of pancreatic ducts
and endocrine cells, and extraordinarily high expression of the receptor
tyrosine kinase Axl, an emerging cancer drug target. In proof-of-principle
drug screens, the authors find that PDAweanling mice treated for 2 weeks
with gemcitabine plus Abraxane and inhibitors of Axl signaling (warfarin or
BGB324) have fewer tumor initiation sites and reduced tumor size
compared with KIC mice treated with standard-of-care treatments (either
gemcitabine alone or gemcitabine plus Abraxane).
Implications and future directions
Candidate anti-cancer drugs identified in organ culture or cell-based
screens must be validated for efficacy in preclinical models such as KIC
mice. Rgs16::GFP is a robust and faithful in vivo reporter of PDA
progression and sensitivity to new chemotherapeutic drug regimens,
including Axl-targeted agents. This rapid in vivo screening strategy could
potentially be applied to identify improved therapeutics for many other
cancers.
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initiation and growth. Thus, the in vivo PDA model harboring the
Rgs16::GFP reporter is an efficient system for identifying effective
drug combinations, and for identifying novel or repurposed drugs to
treat PDA.
RESULTS
Rgs16::GFP is a KrasG12D-dependent reporter of PDA
initiation and growth
We introduced the Rgs16::GFP reporter into KC and KIC mice
because PDA initiates in pancreatic duct-like cells, either following
ADM or neoplastic growth of progenitor cells, anywhere from the
head to the tail of the pancreas but not in the hepatopancreatic
duct (supplementary material Fig. S1) (Aguirre et al., 2003). The
affected cell types are consistent with the expression domain of p48
(Ptf1a) during pancreas development (Kawaguchi et al., 2002).
Rgs16::GFP is expressed in embryonic and neonatal pancreatic
ducts (Villasenor et al., 2010) and, in adults, in ducts early in the
response to chronic high insulin demand and in mid-late gestation in
pregnant females (Villasenor et al., 2010). Finally, endogenous
Rgs16 is expressed in human PDA [The Cancer Genome Atlas
(TCGA), http://cancergenome.nih.gov/; Kim et al., 2010].
Analysis of pancreata harvested from postnatal day 29 (P29) mice
demonstrated that Rgs16::GFP expression in pancreatic tumors is
dependent on the (heterozygous) KrasG12D allele; KIC and KC mice
had high Rgs16::GFP expression (Fig. 1). Pancreata in KIC
mice at P29 had widespread ductal neoplasia. No GFP expression
was observed in IC mice (Fig. 1), which do not harbor the KrasG12D
allele and do not develop tumors. Background fluorescence
wasminimal inKICmice lacking theGFP transgene (data not shown).
An important advantage of the Rgs16::GFP;KIC reporter mice
is that the entire pancreas can be rapidly evaluated under a
fluorescence dissection microscope to quantitate non-overlapping
regions of GFP expression. In hundreds of pancreata dissected at
multiple ages, every neoplastic lesion detected in bright-field
microscopy expressed Rgs16::GFP (e.g. supplementary material
Fig. S1A,B). A three-dimensional rotational movie shows
Rgs16::GFP expression in a PDA tumor, several small areas of
neoplasia and normal acinar cells in lobes at the head of the pancreas
(supplementary material Movie 1; Fig. S2).
Rgs16::GFP intensity increases with PDA initiation and
growth
In KIC mice, Cre-recombinase is first expressed by the p48 (Ptf1a)
promoter in the embryonic progenitor cells that give rise to the three
epithelial cell lineages in the adult – ducts, and exocrine and
endocrine pancreas (Kawaguchi et al., 2002). Therefore, all cells
in these pancreatic lineages express oncogenic KrasG12D and the
tumor suppressor gene Cdkn2a is deleted (see supplementary
material Fig. S3: the entire pancreas is marked by TdTomato in
p48Cre;LSL-TdT reporter mice). Despite expression of KrasG12D
and deletion of Cdkn2a throughout the pancreas, Rgs16::GFP is
only expressed in a few early PanINs sparsely scattered throughout
the pancreas 2 weeks after birth (P15; Fig. 2A). At P15, the pancreas
appears morphologically and functionally normal, with the
exception of these early PanINs. Thus, Rgs16::GFP reports the
precise region of activated KrasG12D signaling at tumor initiation
and throughout progression.
Fig. 1. Rgs16::GFP is a KrasG12D-dependent reporter of pancreatic neoplasia. Rgs16::GFP is expressed in early pancreatic ductal neoplasia (IPMN, PanIN
and PDA) but not in functional acinar cells of Rgs16::GFP;KIC (GFP-KIC) and Rgs16::GFP; KC (GFP-KC) mice (age=P29). No fluorescence background was
detected in PDA tumors inmice lacking theRgs16::GFP transgene (KIC orKCwithout GFP; not shown) nor inGFP-IC or normal glycemicRgs16::GFP (GFP-WT;
not shown) pancreata. Live fluorescence microscopy is shown. Scale bars: 1 mm.
Fig. 2. Rgs16::GFP is a KrasG12D-dependent reporter of PDA expansion.
(A) Early lesions appear by postnatal day 15 (P15) in Rgs16::GFP;KIC (GFP-
KIC) mice, marked by Rgs16::GFP expression in ducts. As tumors grow, GFP
expression increases. (A; lower panels) Pancreata of normal glycemic,
age-matchedRgs16::GFP (Ctrl) mice. Live fluorescencemicroscopy is shown.
(B) Quantification of GFP expression based on the averages of the highest
intensity pictures of each pancreas of GFP-KIC (G-KIC) and control (G-Ctrl)
mice between P15 to P29. Rgs16::GFP expression increases with age and
PDA expansion. GFP fluorescence of PDA tumors at P29 (arrows) is about
10,000-fold greater than non-tumorigenic, euglycemic Rgs16::GFP mice.
Age and number of mice inRgs16::GFP;KIC [n(G-K)] andRgs16::GFP-Control
[n(G-C)] groups are noted.
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Between the ages P15 to P29, average GFP fluorescence
increased more than 100-fold as early PanINs appeared
throughout the pancreas and PDA tumors grew (Fig. 2B). P29 is
therefore an optimal time to assess tumor growth in weanlings
because individual tumors achieve near-maximal brightness, more
than 10,000-fold above background fluorescence.
Rgs16::GFP is expressed in ADMs, PanINs and PDAs
Pancreatic neoplasia secrete mucins and other polysaccharide-
decorated proteins detected by Alcian Blue/Periodic Acid-Schiff
(AB/PAS) staining. PDAs in KIC mice have intense Rgs16::GFP
expression (supplementary material Fig. S4) but little or no AB/PAS
staining, whereas Rgs16::GFP is significantly lower in regions of
neoplasia that are AB/PAS-positive (Fig. 3, inserts). High-resolution
confocal microscopy revealed that Rgs16::GFP is not expressed in
normal acinar cells, consistent with fluorescence microscopy of
dissected pancreata (Figs 1,2). KrasG12D-evoked ADM induced
Sox9 expression, as previously reported (Kopp et al., 2012; Krah
et al., 2015), and low Rgs16::GFP expression was observed in most
cells (Fig. 4). By contrast, Rgs16::GFP expression was significantly
higher and co-expressed with Sox9 in duct-like PanIN lesions,
consistent with the findings shown in Fig. 3. The marker of
proliferation-competent cells, Ki67, was co-expressed with
Rgs16::GFP in many cells within PDAs and PanINs but almost
never in regions of ADM (supplementary material Fig. S5). This
pattern of high Rgs16::GFP expression in PanINs and PDAs was
confirmed by immunofluorescencewithMuc1, Ecad and endogenous
Rgs16 (Fig. 4, Fig. 5A). Exceptional cases induced intense Rgs16::
GFP expression in acinar-like cells (supplementary material Fig. S6)
co-expressing high carboxypeptidase A1 (CPA1; supplementary
material Fig. S7). This pattern was observed in peripheral lobes with
edema that sit beyond (proximal to) tumor nodules in KIC pancreata.
These seem to be specialized responses in which Rgs16 and CPA1
expression is secondary to PDA tumor growth.
Rgs16::GFP is expressed in pancreatic ductal progenitor and
PDA cells
KIC mice (6-8 weeks) and PDA primary cells in culture co-
expressed Rgs16::GFP with markers of pancreatic progenitor cells
and epithelial-mesenchymal transition (EMT), such as Sox9, Muc1
and Ecad (Fig. 4, Fig. 5C; β-catenin and TGF-β supplementary
material Fig. S8). Orthotopic transplantation of Rgs16::GFP+
primary cells derived from PDA tumors at 6 weeks rapidly
regenerated GFP-positive pancreatic cancer in duct-like structures
in close proximity with vasculature in recipient NOD-SCID mice
(Fig. 5B). By contrast, stroma of the non-transgenic host did not
express GFP.
To gain more information about the gene expression profile of
the KIC PDA cells, we performed RNA sequencing (RNA-Seq)
analysis of the transcriptome, and found that PDA cells in primary
culture are closely related to embryonic (E13.5) pancreas (Fig. 5D,E).
PDA cells and E13.5 progenitor cells of the ductal and endocrine
lineages expressed Pdx-1 and Sox9 (Fig. 5F). Similarities in the
transcriptomes diverged noticeably by E17.5 and E18.5, as pancreata
begin to express more genes in maturing endocrine and exocrine
cells, and fewer mesenchymal genes. The transcriptomes of PDA
primary cells and normal adult pancreas are only distantly related;
PDA cells did not express appreciable levels of markers of mature
acinar or endocrine cell types.
In a survey of cancer-associated receptors and ligands in primary
PDA cells in culture, we noted that the receptor tyrosine kinase Axl
Fig. 3. Rgs16::GFP expression in pancreatic
neoplasia. Hematoxylin and eosin (H&E) staining for
nuclear/cytoplasmic boundaries, Alcian Blue and
Periodic Acid-Schiff (AB/PAS) staining for mucinous
regions, and GFP staining for Rgs16 expression are
shown in serial sections of Rgs16::GFP;KIC (GFP-KIC)
pancreas. Inserts compare a representative region that is
AB/PAS-positive but GFP-negative at low resolution. WT,
wild type. Scale bars: 500 μm.
Fig. 4. Rgs16::GFP in ADMs, PanINs and PDAs. Confocal images of
immunofluorescence staining show Rgs16::GFP expression relative to
Ecad (red), Sox9 (green) or Muc1 (green) in normal and neoplastic pancreas
(ADM, PanIN, PDA) in KIC mice (P29). Primary features of particular interest
(e.g. PanIN in the same field as ADM) are indicated by bold white arrows. Other
features of interest (e.g. Sox9 expressed in ADM) are indicated by a white
outlined arrow.
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was highly expressed, with modest expression of its endogenous
ligand Gas6 (Fig. 5F, Table 1). Axl and Gas6 are highly expressed in
many human primary PDA tumors (TCGA data), containing both
cancer and stromal cells. Axl was the most highly enriched receptor
kinase expressed in PDA cells for which we had inhibitors of active
ligand maturation and receptor antagonists to test PDA initiation and
progression. Furthermore, Axl is associated with EMT and drug
resistance in carcinomas (Zhang et al., 2012; Byers et al., 2013).
Therefore, we sought to establish a rapid in vivo assay to assess the
effect of clinical Axl inhibitors on PDA initiation and progression.
A 2-week in vivo assay: PanIN and PDA tumor growth is
suppressed at P29 by a combination of Axl inhibitors,
gemcitabine and Abraxane
The therapeutic screening strategy was to treat KIC pups between
P15-P28 (when PanINs and PDAs are in rapid expansion) with
Table 1. Axl and Gas6 mRNA in PDA, embryonic and adult pancreas
Therapeutic
Primary target in PDA
RNA-Seq (FPKM)
PDA culture
Pancreas
Cell type Gene E13.5 E18.5 Adult
BGB324 Cancer cell Axl 66.70 6.47 8.25 4.10
Warfarin Cancer cell and stroma Gas6 1.39 3.43 17.42 14.10
BGB324 inhibits Axl kinase; warfarin inhibits γ-carboxylation of Gas6.
RNA-Seq samples: PDA culture, n=2; E13.5, n=1; E18.5, n=5; adult, n=5.
FPKM, fragments per kilobase of exon per million fragments mapped.
Fig. 5. Primary PDA cells express markers of pancreatic progenitor cells. (A) Endogenous Rgs16 protein is expressed in ducts of primary tumors. Anti-
Rgs16 immunohistochemical staining (brown) of a KIC mouse pancreas. The insert shows a section from the same tumor not stained with primary antibody.
Background staining is Alcian Blue and Periodic Acid-Schiff. (B) Single cell suspension of PDA cells from tumor at 6 weeks transplanted orthotopically into aNOD-
SCID recipient forms large tumors within 2 weeks. The close proximity of duct-like cancer (green; Rgs16::GFP) and vasculature (red; PECAM) is indicated by
white arrows. Scale bar: 100 μm. (C) Primary tumor; Rgs16::GFP (green) and Muc-1 (red) are co-expressed (overlap appears yellow) in PanIN lesions of the
ductal epithelium (white arrow). (D) Cluster dendrogram of RNA-Seq gene expression profiles. The dendrogram was obtained by hierarchical clustering of
pairwise distances between all samples using normalized gene expression values. Each branch represents a sample: E18.5 and adult pancreas (five replicates
each), PDA primary cell culture (cells sorted into Rgs16::GFP-positive and GFP-negative samples), E13.5 and E17.5 (one sample each). (E) 3D scatterplot
showing dissimilarity between samples. We computed Euclidean distance between each pair of samples and scaled these distances using multidimensional
scaling for representation in 3D space. Each axis represents a dimension and axis values represent range of dissimilarities between samples. (F) Heatmap
showing the expression of markers in each sample. We selected a set of markers for developmental stages and computed the z-score to portray their relative
expression levels in each sample. Red represents higher expression and green represents lower expression compared to population mean.
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anticancer drugs, sacrifice mice at P29, and capture Rgs16::GFP
intensity with a dissection fluorescence microscope. Images of the
five brightest non-overlapping fields of Rgs16::GFP expression
were then collected, representing the regions of greatest tumor
burden (supplementary material Fig. S9). This quantitative
protocol represents a much more rapid approach (about 5% of the
time) than traditional histology for analysis of the entire pancreas
from each mouse in a cohort of 20 adults.
To validate this in vivo screening approach, we treated KIC mice
with gemcitabine+Abraxane (GA), a current standard-of-care for
PDA therapy (Von Hoff et al., 2013). GA therapy significantly
reduced PanIN lesions throughout the pancreas (supplementary
material Fig. S9B; note the fields of low GFP expression in treated
animals compared to untreated animals), and reduced average and
median GFP expression (Fig. 6B). GA was more effective than
gemcitabine alone at inhibiting PanIN initiation, relative to
untreated controls (supplementary material Figs S9, S10,
statistical analysis in supplementary material Tables S1, S2).
Thus, this method detected that a standard-of-care drug treatment
was able to impede tumor growth. However, toxic side effects
inhibited growth of weanling mice (supplementary material
Fig. S11). Furthermore, although GA treatment reduced PanIN
lesions, large PDA tumors emerged at the same frequency in
untreated and GA-treated mice (three trials), consistent with its
modest effects in humans (Becker et al., 2014). As in humans, tumor
heterogeneity exists between mice, reflected by differences in
Rgs16::GFP expression levels, histology, immunofluorescence and
response to treatment in KIC mice. Heterogeneity also exists within
each pancreas – some regions were apparently unaffected at P29
whereas other areas had ADM, PanIN, and/or small or large PDA
tumors.
To address whether blocking Axl signaling would improve GA
effectiveness, we tested two clinical Axl inhibitors, BGB324
(Ben-Batalla et al., 2013) and warfarin, in combination with GA in
PDA primary cell culture and KIC Rgs16::GFP reporter mice. In
PDA primary cell culture, high concentrations of gemcitabine killed
cells, and BGB324 was cytostatic, but warfarin had no effect
(supplementary material Fig. S12). In KIC mice, warfarin had no
effect by itself but, when combined with gemcitabine+Abraxane
(WGA), PanIN lesions were further reduced and, importantly,
WGA significantly reduced the growth of large PDA tumors
observed in untreated and GA-treated mice (Fig. 6). Similar
inhibitory effects were seen when GA was combined with
BGB324 (BGA) or warfarin plus BGB324 (WBGA) (Fig. 6).
Together, these data demonstrate that this screening strategy in KIC
Rgs16::GFP mice is a relatively rapid means for identifying novel
Fig. 6. A 2-week in vivo assay: PDA tumor growth and PanINs suppressed at P29 by Axl inhibitors+gemcitabine+Abraxane. (A) The two highest intensity
images of Rgs16::GFP;KICmice at P29 are shown for the (a,b) untreated (Untr), (c,d) warfarin (W), (e,f ) gemcitabine and Abraxane (GA), and (g,h) warfarin with
gemcitabine and Abraxane (WGA) groups. (B) Gemcitabine+Abraxane (GA) with the Gas6/Axl inhibitors warfarin (dark blue dots; WGA, n=14), BGB324 (light
blue dots; BGA, n=15) or both (WBGA, black dots on the right, n=24) inhibit growth of large PDAs and reduce PanINs throughout the pancreas (many fields with
little or no GFP; n=53). GA alone (green dots, n=30) reduces PanINs but resistant tumors occur (many fields with high GFP). Warfarin alone (W, pale blue dots on
the left, n=16) has no effect, similar to untreated control (U, black dots on the left, n=42). WGA, BGA and WBGA show pancreata from individual mice; each
column of five dots represents one pancreas, each dot a single micrograph, non-overlapping fields from 1st to 5th brightest (quantitated by ImageJ; statistics in
supplementary material Table S1). All of the untreated (U), gemcitabine+Abraxane (GA), and warfarin (W) group images are collapsed into a single vertical
alignment each to save space. The response to gemcitabine alone (n=30) and gemcitabine+warfarin (n=33) is shown in supplementary material Fig. S10;
statistics in supplementary material Table S2. Control mice (Ctrl, Rgs16::GFP transgenics, gray lines, n=24) are represented as one line per mouse. The 95-
percentile and 1-percentile of all image values within untreated group are depicted with dashed horizontal lines and the percentage of micewith images above and
below, respectively, of these values are indicated for each group. Small alphabetical letters correspond to images in panel A. Mean log (GFP) of each group is
shown (supplementary material Table S1). Pancreata of untreated PDA mice express significantly more Rgs16::GFP than treated groups (GA, BGA, WGA).
Student’s t-test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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or repurposed drugs, as well as new drug combinations, for
treatment of Kras-dependent PDA.
DISCUSSION
The dismal survival rate of patients diagnosed with pancreatic
cancer justifies an intense preclinical effort to identify novel PDA
therapeutics. GEMMs have substantial benefits for drug screening,
including recapitulation of all major stages of PDA and the complex
interplay between precancerous neoplasia, adenocarcinoma,
immune components and stromal elements (Cook et al., 2012).
We used the KIC model because it is currently the most aggressive
GEMM of PDA available (Aguirre et al., 2003). KIC mice harbor
the two earliest genetic mutations common to most individuals with
PDA: oncogenic mutations in Kras, which confer GAP-resistance
(e.g. KrasG12D), and deletions of the tumor suppressor Cdkn2a. In
the KIC GEMM, neoplasia initiate around 2 weeks of age and
tumors (1-2 mm) develop in all untreated mice by P29.
Furthermore, toxic and off-target drug effects inhibit growth of
weanling mice and are easily measured as reduced body weight
(supplementary material Fig. S11). Although weanlings might be
hypersensitive to toxic drugs, the screen allows a rapid assessment
of in vivo drug efficacy and specificity in weanling pups at a
relatively modest cost.
To accelerate the discovery of effective drugs that inhibit PDA
in vivo, we developed Rgs16::GFP as a sensitive reporter of PanIN
and PDA initiation, progression and tumor size by 4 weeks of age
(P29) in KIC mice. Rgs16::GFP expression is KrasG12D-dependent
in KC and KICmice. GFP is not expressed in ICmice (which do not
develop neoplasia), and PDAs that develop in the GEMMs have no
background fluorescence in the absence of the GFP transgene.
Endogenous Rgs16 is not abundant in normal adult exocrine
pancreas, nor is it usually induced in dedifferentiating (injured)
acinar cells early in the process. For example, Rgs16 is not induced
in the pancreas (primarily acinar cells) of adult Ptf1a knockout
(KO) mice, although CPA1 (an acinar cell marker) declines
precipitously during the 2-week progression of acinar cell de-
differentiation (Krah et al., 2015). KrasG12D opposes Ptf1a
maintenance of terminally differentiated pancreas and promotes
acinar dedifferentiation in P29KC andKICmice (Krah et al., 2015).
Widespread, high Rgs16::GFP expression in acinar-like cells
(co-expressing high CPA1; supplementary material Fig. S7) was
sometimes observed in peripheral lobes with edema that sit beyond
(proximal to) tumor nodules in KIC pancreata (supplementary
material Fig. S6). These are specialized responses in which Rgs16
and CPA1 expression is secondary to PDA tumor growth. Tumors
and/or calcified ductal stones might block the duct [analogous to
partial pancreatic ductal ligation (Xu et al., 2008)], and promote
edema and signaling that stimulates this unusually intense co-
expression of CPA1 and Rgs16. Whereas Rgs16 expression
persisted, co-expression with CPA1 in these dedifferentiating
pancreatic lobes was presumably transient, because these
structures (and CPA1) were absent in PanIN and in older KIC
mice with solid tumors occupying the entire transformed pancreas.
An important point is that, although all pancreatic cells in KIC
mice express KrasG12D and have inactivated Cdkn2a (indeed, p48::
Cre drove TdTomato expression throughout the pancreas;
supplementary material Fig. S3), Rgs16::GFP is absent at P15
except for expression in the earliest lesions, and then throughout
tumor progression. Huang et al. (2014) showed that oncogenic Kras
requires GTP loading for enhanced activity. Presumably, Rgs16::
GFP is marking the precise location of, and perhaps the cells directly
engaged in, receptor-dependent activation of KrasG12D signaling.
Thus, these in vivo reporter mice could help to identify drugs that
directly or indirectly inhibit KrasG12D activation during ADM,
PanIN formation and PDA progression.
We used Rgs16::GFP to evaluate novel PDA therapeutic
combinations in a rapid (2 week) in vivo screen. GFP intensity
increased as a function of tumor burden in the pancreas (Fig. 2).
Therefore, drugs and novel small molecules that inhibit PDA
progression in vivo can be readily identified by their ability to reduce
Rgs16::GFP fluorescence intensity in dissected pancreata (Fig. 6,
supplementary material Figs S9, S10). We showed that a standard-
of-care combination of gemcitabine+Abraxane (GA) reduced
initiation of neoplasia in KIC;Rgs16::GFP reporter mice.
However, GA did not significantly reduce growth of the largest
pancreatic tumors, consistent with modest effects in prolonging
survival in humans (Becker et al., 2014).
To identify additional genes that might be involved in PDA
initiation and tumor growth, and therefore be potential targets for
drug treatment, we characterized the gene expression profile of
primary PDA cells in culture by RNA-Seq. The transcription profile
of PDA cells was most closely related to embryonic progenitors of
ducts and islets, the same embryonic cell types that express Rgs16
(Villasenor et al., 2010). Rgs16::GFP is a marker of embryonic
pancreatic stem cells at E9.0 in the pancreatic bud, and continues to
be expressed in Sox9-positive duct cells and insulin-positive
endocrine cells at E15.5 (Villasenor et al., 2010). Thus,
monitoring Rgs16 expression might lead to the identification of
receptors and ligands important in stem cell function and cancer
initiation. We found that expression of the tyrosine kinase receptor
Axl was tenfold higher in primary PDA cells compared to normal
embryonic (E13.5) pancreas and 16-fold higher than normal adult
pancreas (Fig. 5F; Table 1), consistent with observations by others
(Song et al., 2011). It was found that Axl and Rgs16 tend to be
coordinately expressed in human PDA primary tumors (from
analysis of co-expression of the human primary PDA samples
characterized in supplementary material Figs S13 and S14). High
levels of Axl expression in advanced cancers from diverse cellular
origins suggest that tumor-cell-associated Axl might be a
fundamental contributor to malignant progression (Holland et al.,
2010). Indeed, our recent results support the notion that Axl signal
transduction is required to maintain epithelial plasticity traits of
aggressive pancreatic tumors, including tumorigenicity,
invasiveness, survival, drug sensitivity and metastasis (Kirane
et al., 2015). Additionally, Axl inhibition has been shown to block
cell migration and reduce metastasis in breast cancer models
(Gjerdrum et al., 2010; Paccez et al., 2013; Dunne et al., 2014;
Paolino et al., 2014).
We found that Gas6, Axl ligand, was expressed in normal adult
pancreas (and primary human PDA tumors; TCGA) but its
expression was tenfold lower in PDA primary culture cells
(Table 1). Warfarin inhibits post-translational γ-carboxylation of
Gas6, which is necessary for its ability to activate Axl signaling
(Lew et al., 2014). Whereas warfarin by itself had no effect on
PDA, warfarin combined with gemcitabine+Abraxane (WGA) had
three important effects in KIC;Rgs16::GFP reporter mice.
Compared to GA therapy alone, WGA further reduced the
initiation of neoplasia, lowered median tumor size, and
significantly reduced growth of the largest tumors. We used low
doses of WGA that have, individually, proven safe in humans.
WGA retarded growth in weanling mice but this is attributable to
gemcitabine and Abraxane. We have recently shown that warfarin
exerts its anti-cancer effects by inhibiting Gas6-mediated Axl
activation in PDA tumor cells (Kirane et al., 2015). A selective Axl
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kinase inhibitor, BGB324, had similar effects on PDA initiation
and growth when combined with GA (manuscript in preparation).
Systemic Axl inhibition might also exert anti-tumor effects through
host-response-dependent mechanisms (Paolino et al., 2014; Kirane
et al., 2015). We screened a total of 53 mice with GA plus warfarin
or BGB324. All mice survived treatment from P15 to P29, and
about 40% had lower rates of neoplasia compared to the control
mice that we analyzed.
Rgs16::GFP expression is essentially extinguished in pancreas of
normal, euglycemic mice by P15 and completely absent by P28
(Villasenor et al., 2010). By contrast, Rgs16::GFP expression in the
largest PDA tumors was about 1-million times brighter than control
pancreas, or regions of KIC pancreas not yet affected by KrasG12D
expression. Equally important for identification of the most
effective PDA therapeutics, the median GFP expression in
untreated mice was 1000-fold higher than non-GFP KIC mice, or
Rgs16::GFP control mice lacking PDA.Warfarin+GA significantly
retarded PDA initiation and progression. Although this in vivo assay
is sensitive and rapid, it is primarily a chemopreventive screen in
young animals, whereas PDA typically initiates in middle age and
is diagnosed late in life. Therefore, the best drug candidates
identified in this rapid in vivo assay should be validated in survival
and tumor regression studies in adults. An early phase clinical trial
is under consideration for low-dose warfarin based on the
combination of findings we report here, other preclinical studies
(Brown, 1973; McCulloch and George, 1987; Schulman and
Lindmarker, 2000; Kirane et al., 2015) and anecdotal observations
in patients (Brown, 1973; McCulloch and George, 1987; Schulman
and Lindmarker, 2000; Kirane et al., 2015). Although we still found
significant tumor progression in WGA-treated KICmice, this might
be caused by other receptors activating KrasG12D. Further inhibition
might be achieved by adding another inhibitor to the combination
therapy.
In summary, the screening method described here reveals
sensitivity to new drug regimens that inhibit KrasG12D-mediated
oncogenesis. These findings suggest that patients with successful
resection of PDA and clear margins of resection might benefit most
from repurposed low-dose warfarin treatment in combination with
gemcitabine chemotherapy. Future studies will test new drugs as
they become available to help identify the most effective and
targeted PDA therapeutics.
MATERIALS AND METHODS
Mouse lines and genotyping
The mouse lines used were KIC ( p48Cre/+; KrasG12D/+; Cdkn2af/f ); KC
(p48Cre/+; KrasG12D/+); IC (p48Cre/+; Cdkn2af/f ); Rgs16::GFP; KIC [KIC
mice crossed with Rgs16::GFP BAC transgenic mice to generate Rgs16::
GFP;p48Cre/+;KrasG12D/+;Cdkn2af/f (Rgs16::GFP;KIC) reporter mice].
Genotyping was done using clipped tails before sacrifice and confirmed
with spleen DNA after dissection. Mice were maintained at a 12-h day, 12-h
night cycle on normal chow ad libitum according to the rules and standards
of UT Southwestern Institutional Animal Care and Use Committee. Rgs16
mice were identified by blue light excitation of GFP in the brain of newborn
pups or in the retina of adult mice. Genotyping of KIC mice was done with
the following primers: p48Cre (For: 5′-CCTGGAAAATGCTTCTGTCCG-
3′; Rev: 5′-CAGGGTGTTATAAGCAATCCC-3′; product: 392 bp), LSL-
KrasG12D (For: 5′-CTAGCCACCATGGCTTGAGT-3′; Rev: 5′-TCCGA-
ATTCAGTGACTACAGATG-3′; product: 327 bp) and Cdkn2af/f (For: 5′-
TTGTTGGCCCAGGATGCCGACATC-3′; Rev: 5′-CCAAGTGTGCAA-
ACCCAGGCTCC-3′; product: 145 bp for wild type, 179 bp for loxP
inserted allele). All PCR conditions started with genomic denaturation at
94°C for 10 min followed by 33 cycles of 94°C denaturation for 30 s,
60°C annealing for 1 min, and 72°C elongation for 1 min. PCR products
were run in a 1% agarose gel.
Fluorescent microscopy and GFP quantification
Pancreatic expression of Rgs16::GFP in Rgs16::GFP;KIC mice was
captured under a Zeiss Lumar tissue dissection microscope (eye piece
=10×) with Filter Set Lumar 13 (excitation: BP 470/20, emission: BP 505-
530) illuminated by Osram HBO 103 W/2 mercury short-arc (without
reflector) fluorescent lamp. The microscope objective was NeoLumar S
(0.8×, FWD 80 mm) and the total image magnification was selected to be
25.5×. Images were captured via a single-channel camera (Hamamatsu
60-C, 1″, 1×) in 1344×1024 resolution with 1 s exposure and 1×1 binning,
analog gain=10, and analog offset=2 settings. Pancreatic fields representing
the tumor burden (three to four fields for P15 pups and five or more for pups
from P23 onwards) of the pancreas were imaged, covering up to 50% of the
organ surface area. All images were saved in gray-scale 16-bit tiff format.
Images were quantified using NIH ImageJ software with background
subtraction with a radius of 50 pixels. A variable and tight threshold was set
to eliminate residual background. Intensities of all particles with size ≥5
pixels were summed to obtain the total light intensity per image.
Tissue clearing and microscopy
Pancreata and a small section of duodenum containing the ampulla of Vater
were dissected, fixed overnight in PFA, and washed in PBS (4°C). Tissues
were stored in PBS (4°C). Tissue clearing and microscopy was done as
described by Soderblom et al. (2015), based on previous studies (Becker
et al., 2012; Kopp et al., 2012; Krah et al., 2015). Production of the three-
dimensional (3D) rotational movie was done as described by Soderblom
et al. (2015) using IMARIS.
Drug dosages
Rgs16::GFP;KICmice were injected intraperitoneally with gemcitabine (Eli
Lilly; Indianapolis, IN, USA) (12.5 mg/kg body weight/day given 3 days/
week, dissolved in PBS), Abraxane (Cellgene; Summit, NJ, USA) (5 mg/kg
body weight/day given 2 days/week, diluted in 2% saline solution), BGB324
(BerGenBio, Bergen, Norway) (5 mg/kg body weight/day given 5 days/
week, dissolved in a mix of DMSO:ethanol:Kolliphor EL:water with
4:4:8:84 v/v ratio), and warfarin (0.2 mg/kg body weight/day given 5 days/
week, dissolved in PBS) according to the injection schedules specified in
supplementary material Fig. S9. These doses were validated in previous
mouse studies (Dineen et al., 2010; Kutluk Cenik et al., 2013; Ostapoff et al.,
2013, 2014; Aguilera et al., 2014). Note that 30% cyclodextrin was
discontinued as a vehicle for BGB324 (v2B, v2G) because it was not
active. GA was not affected (supplementary material Fig. S9; GA_v2B,
GA_v2G). To verify that tumor progression remains constant over the
duration of these experiments, assays of untreatedmicewere interspersedwith
drug-treated cohorts, and warfarin-treated pups were the final cohort we
tested. Gemcitabine, Abraxane and warfarin were purchased from the UT
Southwestern clinical pharmacy; BGB324 was a gift from BerGenBio.
Rgs16::GFP PDA primary cell culture
Primary Rgs16::GFP PDA cells were harvested from 6-week-old KICmice.
Cells were grown in 25 mM Glucose DMEM (HyClone) with 10% FBS
(Serum Source International), penicillin and streptomycin (Life
Technologies) on rat tail collagen type 1 (BD Biosciences) coated plates
(0.5 µg/cm2) in a humidified incubator at 37°C and 5% CO2. Cells reaching
confluency were washed twice with PBS (HyClone) and lifted with 0.05%
Trypsin-EDTA (HyClone) treatment up to 10 min in the incubator. For drug
tests in supplementary material Fig. S12, primary PDA cells were incubated
with gemcitabine (10 μM dissolved in PBS), warfarin (1 μM or 10 μM
dissolved in water), BGB324 (1 μM or 10 μM dissolved in DMSO) or
warfarin and BGB324 together for 24 h in a 37°C incubator. PDA live cell
numbers were obtained via counts using a hemocytometer following 2%
trypan blue staining to distinguish dead cells under an inverted microscope.
PDA primary cell RNA-Seq
Cultured Rgs16::GFP PDA cells were stimulated with 40% FBS containing
growth medium, incubated overnight and subjected to FACS to separate
the GFP-positive and -negative cell populations. After isolating RNA via
TRIzol (Life Technologies) treatment, the transcriptional profile of each
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GFP-PDA population was revealed via RNA-Seq performed on poly-A
selected mRNA. Mouse sequence reads were aligned to the mm9 genome
assembly using TopHat v2.0.9 (Trapnell et al., 2009). All default settings
were used except: -G option and -no-novel-juncs. The Cuffdiff module
available in Cufflinks software v2.1.1 was used to quantify the expression
by the FPKM method (Trapnell et al., 2010, 2012). The geometric method
(median of the geometric means of fragment counts across all libraries) was
used to normalize and scale FPKM values.
Dendrogram –mouse PDA culture and tissues
We calculated pair-wise distances between all array sample expression data
using the ‘euclidean’ method in dist () R function to check the similarities
between samples. This method calculates the distance between the two
vectors. We performed hierarchical clustering on this distance matrix using
the ‘ward’ method in hclust () R function.
Dendrogram – TCGA RNA-Seq
We extracted pancreatic adenocarcinoma patient sample (n=178) mRNA
expression data available from The Cancer Genome Atlas (TCGA). These
data contain normalized gene expression in terms of transcripts per million
(TPM) and these values were used for the further analysis. To compare
expression levels in the human PDA tumor samples with mouse samples, we
used the NCBI homologene database to extract mouse homolog genes for
human genes. From this list, we selected genes that show ≥10 TPM in at
least 10% of the human primary tumor samples. This filter retained 10,135
genes used to plot the dendrogram.
Multidimensional scaling
We used multidimensional scaling (MDS) to assess the differences between
samples. For this, we used normalized expression matrix for all genes in the
genome across all samples and computed distances between each sample
pair using the euclidean method; cmdscale () in stats R package (R
Development Core Team, 2014) was used to represent these distances
between each pair of samples in 3D space.
Heatmap
Z-score was computed for a selected set of markers in each category across
all samples and plotted using heatmap.2 () function available in gplots R
package (Warnes et al., 2015).
Statistical analysis of GFP expression
GFP values were converted to log10 scale prior to statistical analysis. Graphs
and their statistical comparisons were done using GraphPad Prism software
with unpaired and two-tailed Student’s t-test. Significance between groups
was indicated as ns (not significant); *P<0.05; **P<0.01; ***P<0.001;
****P<0.0001. Error bars in all the graphs are standard error of the mean
(s.e.m.). See supplementary material Tables S1 and S2 for additional
statistical analysis.
This article is part of a subject collection on Model Systems in Drug Discovery: from
Bench to Patient. See related articles in this collection at http://dmm.biologists.org/
cgi/collection/drugdiscovery
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